News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Beijing Vigoo Biological Says EV71 Vaccine Passes Phase III Test


5/30/2013 9:33:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

May 29, 2013 -- Beijing Vigoo Biological, a vaccine-focused subsidiary of China National Biotec Group, reported that its Enterovirus 71 vaccine was effective in up to 90% of test subjects. The company carried out a large Phase III trial in 10,245 children, aged 6 to 35 months. Half were randomized to receive vaccine. EV71, which strikes mainly children under the age of five, is a major cause of hand, foot and mouth disease. More details....



Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today


comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES